Medical Condition News

RSS

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Life Technologies announces launch of new sequencer to deliver genomic data

Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.

1 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Clinical Data, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pulmonary arterial hypertension (PAH) to PRX-8066, the Company's selective serotonin 2B (5-HT2B) receptor antagonist.

1 Nov 2010

Consumer Reports publishes survey on eyeglass retailers

Shopping for eyeglasses isn't easy, especially when frames can cost well over $200 a pair, even without the fancy add-ons and logos. But a Consumer Reports survey found that a great pair of eyeglasses doesn't have to break the bank.

1 Nov 2010

Global Genes Project launches new campaign to create awareness about rare diseases

The Global Genes Project, a non-profit advocacy organization that aims to raise awareness about the prevalence of rare diseases worldwide, today launched the 7,000 Bracelets for Hope campaign. The 7,000 Bracelets for Hope campaign is designed to draw attention to an estimated 7,000 different chronic, life-threatening and fatal rare diseases and disorders affecting approximately 30 million Americans and millions more globally.

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Biodel receives FDA CRL for Linjeta NDA

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) requesting additional information regarding the company's new drug application (NDA) for Linjeta™ (human insulin [rDNA origin]) injection 100IU/mL for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

Sugar in excess leads to complications

In light of Diabetes Awareness Month, many people are showing increased interest in the topic of sugar and sugar alternatives. With the various forms of sugar available table sugar, high-fructose corn syrup, agave, and honey understanding the differences between sugars and their effects on the body is not all sweet.

1 Nov 2010

American Psychological Association blocking therapists from learning effective treatments for PTSD

In the wake of enormous controversy about its role in the participation of psychologists in the use of torture to extract information from prisoners at Guantanamo Bay and in other parts of the world, an interview just carried by Truthout reveals a new round of criticism that has been directed toward the American Psychological Association (APA).

1 Nov 2010

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Oncimmune® LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, today announced that two oral presentations and five poster presentations during this week's American College of Chest Physicians' (ACCP) annual meeting in Vancouver will collectively highlight the clinical and economic benefits of EarlyCDT-Lung.

1 Nov 2010

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Researchers are calling for clear guidelines on childhood stroke after a study, published in the November issue of Acta Paediatrica, found wide variations in time lag to diagnosis, investigation and treatment.

1 Nov 2010

Diabetes Research Institute kicks off 'Be Part of the CURE' online campaign

Beginning today, thousands of people who want to help put an end to diabetes can be part of the cure by participating in the Diabetes Research Institute Foundation's online campaign at BePartoftheCure.org. Kicking off National Diabetes Awareness Month, the Be Part of the CURE campaign is a fun and meaningful way for people living with diabetes, their family and friends, and anyone concerned about curing this devastating disease to literally participate in the "CURE."

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

An overwhelming majority of Breast Cancer Surveillance Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) in the U.S. are up-to-par with American College of Radiology Imaging Network (ACRIN) and European Society of Breast Imaging (EUSOBI) technical standards and requirements, according to a study in the November issue of the Journal of the American College of Radiology.

1 Nov 2010

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.

1 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

Building on a plan announced in September of 2007, UC San Diego Health Sciences and the Department of Radiation Oncology are pleased to announce an agreement with Proton Health Partners, LLC (PHP) to plan, develop, and operate The UC San Diego Proton Therapy and Research Center.

1 Nov 2010

Medical Condition News

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Life Technologies announces launch of new sequencer to deliver genomic data

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Consumer Reports publishes survey on eyeglass retailers

Global Genes Project launches new campaign to create awareness about rare diseases

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Biodel receives FDA CRL for Linjeta NDA

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

Sugar in excess leads to complications

American Psychological Association blocking therapists from learning effective treatments for PTSD

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Diabetes Research Institute kicks off 'Be Part of the CURE' online campaign

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Mechanism of rogue cell killer discovered

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News